Background. Resistin is a major adipose tissue cytokine implicated in insulin resistance, inflammation and vascular damage. This cytokine is raised in patients with end-stage kidney disease (ESKD) but the relationship between resistin and major clinical outcomes has not been investigated in this population. Methods. We studied the mutual relationship between resistin and the two major adipokines (adiponectin and leptin) and the interaction between resistin and adiponectin (ADPN) and all-cause and cardiovascular (CV) mortality in a cohort of 231 haemodialysis patients followed up for 57 ± 44 months.

, , , ,,
Nephrology, Dialysis, Transplantation
Department of Internal Medicine

Spoto, B., Mattace Raso, F., Sijbrands, E., Pizzini, P., Cutrupi, S., D'Arrigo, G., … Mallamaci, F. (2013). Resistin and all-cause and cardiovascular mortality: Effect modification by adiponectin in end-stage kidney disease patients. Nephrology, Dialysis, Transplantation, 28(SUPPL.4). doi:10.1093/ndt/gft365